ReviewClinical microbiology reviews2017
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.
Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 218 citations in OpenAlex.
- Association between BK polyomavirus and prostate cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prevalence of BK virus and BK virus-associated hemorrhagic cystitis in stem cell transplant recipients: a systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- Immune Responses to BK Virus in Renal Transplant Recipients Receiving Intravenous Immunoglobulin Treatment.The Journal of infectious diseases · 2026Trial
- BKV activates the interferon-β response in primary and immortalized microvascular endothelial cells late in the infectious cycle, resulting in persistence.Journal of virology · 2026Article
- Urinary microbiome in renal transplant patients with BK polyomavirus reactivation.Journal of medical microbiology · 2026Article
- Computational Design and Biopharmaceutical Evaluation of a Chimeric Nanoparticle Vaccine for Targeted Delivery against BK Polyomavirus.Pharmaceutical research · 2026Article
- Review
- Characterization of the urinary DNA virome of hematopoietic stem cell transplant recipient and healthy cynomolgus macaques.bioRxiv : the preprint server for biology · 2026Article
- BKPyV-Co-Architect of the Fate of a Renal Transplant During a One-Year Observation Period.International journal of molecular sciences · 2026Article
- BK virus kinetics and associated cystitis/urethritis symptoms after PTCy-based allogeneic hematopoietic cell transplant.Blood advances · 2026Article
- Unveiling the mediating role of immune cells in the link between pathogen infections and Hashimoto's thyroiditis.The Journal of international medical research · 2026Article
- Polyomavirus Infection in Two Young Parrots: Assessment of Viral Distribution in Organs and Affected Tissues.Veterinary medicine international · 2026Article
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Prolonged Prophylactic Ureteral Stent Placement and BK Polyomavirus Infection After Renal Transplantation-A Retrospective Case-control Study.European urology open science · 2025Article
- Detection of the BK virus in urban wastewater inlets into the Karun River.Iranian journal of microbiology · 2025Article
- Long-term kidney side effects of allogeneic hematopoietic stem cell transplantation in children.Pediatric nephrology (Berlin, Germany) · 2025Article
- ISG20 RestrictsMicroorganisms · 2025Article
- Updates in the Diagnosis and Treatment of BK Viraemia in Kidney Transplant Recipients: Current and Future Insights.Journal of clinical medicine · 2025Review
- Review
- NaCl and urea modulate CD8+ T cell survival, renal accumulation, and response to BK virus.JCI insight · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK polyomavirus (BKV) causes frequent infections during childhood and establishes persistent infections within renal tubular cells and the uroepithelium, with minimal clinical implications. However, reactivation of BKV in immunocompromised individuals following renal or hematopoietic stem cell transplantation may cause serious complications, including BKV-associated nephropathy (BKVAN), ureteric stenosis, or hemorrhagic cystitis. Implementation of more potent immunosuppression and increased posttransplant surveillance has resulted in a higher incidence of BKVAN. Antiviral immunity plays a crucial role in controlling BKV replication, and our increasing knowledge about host-virus interactions has led to the development of improved diagnostic tools and clinical management strategies. Currently, there are no effective antiviral agents for BKV infection, and the mainstay of managing reactivation is reduction of immunosuppression. Development of immune-based therapies to combat BKV may provide new and exciting opportunities for the successful treatment of BKV-associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.